

10. Teh M, Wee A, Raju GC. An immunohistochemical study of p53 protein in gallbladder and extrahepatic bile duct/ampullary carcinomas. *Cancer* 1994;74:1542–5.
11. Washington K, Gotffried MR. Expression of p53 in adenocarcinoma of the gallbladder and bile ducts. *Liver* 1996;16:99–104.
12. Argani P, Shaukat A, Kaushal M, Wilentz RE, Su GH, Sohn TA, *et al.* Differing rates of loss of Dpc4 expression and of p53 overexpression among carcinomas of the proximal and distal bile ducts: evidence for a biologic distinction. *Cancer* 2001;91:1332–41.
13. Diamantis I, Karamitopoulou E, Perentes E, Zimmerman A. P53 protein immunoreactivity in extrahepatic bile duct and gallbladder cancer: correlation with tumor grade and survival. *Hepatology* 1995;22:774–9.
14. Suto T, Sugai T, Nakamura D-I, Funato O, Nitta H, Sasaki R, *et al.* Assessment of the expression of p53, MIB-1 (Ki-67 antigen), and argyrophilic nucleolar organizer regions in carcinoma of the extrahepatic bile duct. *Cancer* 1998;82:79–85.
15. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. *J Immunol* 1984;133:1710–5.
16. Hahn SA, Bartsch D, Schroers A, Galehdari H, Becker M, Ramaswamy A, *et al.* Mutations of the *DPC4/Smad4* gene in biliary tract carcinoma. *Cancer Res* 1998;58:1124–6.
17. Hahn SA, Schutte M, Hoque AT, Moskaluk CA, da Costa LT, Rozenblum E, *et al.* DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. *Science* 1996;271:350–3.
18. Schutte M. *DPC4/SMAD4* gene alterations in human cancer and their functional implications. *Annu Oncol* 1999; 10(Suppl 4):56–9.
19. Schutte M, Hruban RH, Hedrick L, Cho KR, Nadasky GM, Weinstein CL, *et al.* *DPC4* gene in various tumor types. *Cancer Res* 1996;56:2527–30.
20. Riggins GJ, Kinzler KW, Vogelstein B, Thiagalingam S. Frequency of Smad gene mutations in human cancers. *Cancer Res* 1997;57:2578–80.
21. Zhou S, Buckhaults P, Zawel L, Bunz F, Riggins G, Dai JL, *et al.* Targeted deletion of Smad4 shows it is required for transforming growth factor b and activin signaling in colorectal cancer cells. *Proc Natl Acad Sci U S A* 1998;95:2412–6.
22. Rijiken AM, Hu J, Perlman E, Morsberger LA, Long P, Kern SE, *et al.* Genomic alterations in distal bile duct carcinoma by comparative genomic hybridization and karyotype analysis. *Genes Chromosomes Cancer* 1999;26: 185–91.

Book Review

McKee GT: *Cytopathology of the Breast*, 312 pp, New York, Oxford University Press, 2002 (\$172.00).

Breast cytopathology is a field of diagnostic pathology that has developed most rapidly during the past 10 years. Fine needle aspiration of breast has its established role as a diagnostic tool. It is truly “visually pleasing and diagnostically satisfying,” if everything is done right.

This book is a valuable addition to several already existing books and chapters dealing with breast cytopathology. It contains 16 chapters covering all aspects of breast cytology, including normal breast, non-neoplastic lesions, neoplastic lesions, male breast lesions, and nipple cytology. The prognostic markers are discussed in the last chapter. Cytological features in each category are described in detail. A summary of cyto-

logical features under each topic, along with the tables, are features to be found most useful by practicing pathologists. Pitfalls in each diagnostic category also are discussed. The histology and cytology illustrations are full and in color; most are of high quality. Only a few cytology pictures are suboptimal, partly due to the three-dimensional nature of cytology specimens, which are difficult to photograph at high magnification.

I also liked the format. It has the size of a handbook. It should serve well to the residents, fellows, and pathologists in practice who deal with breast cytopathology.

Fang Fan

*University of Kansas Medical Center
Kansas City, Kansas*